DOCSLIB.ORG

Rational Design of Vaccines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rational Design of Vaccines © 1997 Nature Publishing Group http://www.nature.com/naturemedicine COMMENTARY• Rational design of vaccines The recombinant pertussis vaccine induces early and long-lasting protection 2 A few years ago Sir Gustav Nossal re­ lular pertussis vaccines • Most of these vac­ ported in a book that during the fifties RINO RAPPUOLI cines contain a form of PT detoxified by the Nobel Prize winner Joshua Leder berg chemical treatment (that is, by glutaralde­ "frequently voiced the view that the presently available vac­ hyde, formaldehyde, hydrogen peroxide), a procedure that was cines were a scandal." He questioned "how could we inject our developed at the beginning of the century to detoxify other children with the horrible mixture of substances present in toxins such as diphtheria and tetanus'. The vaccine here de­ killed H. pertussis," and pushed for the use of modern science to scribed is unique, because it contains a mutated, nontoxic form develop "defined molecular vaccines'n. of pertussis toxin that is genetically detoxified. The mutant Some forty years later the challenge proposed by Joshua toxin is produced by an engineered strain of Bordetella pertussis Lederberg has been successfully taken up and his dream of see­ containing the pertussis toxin gene that has been modified by ing defined molecular vaccines has been fulfilled (see Table 1 site-directed mutagenesis in order to introduce two amino acid for the key steps). The substitutions (Arg9~Lys and most advanced scientific Table 1 Key steps of the development Glu129~Gly), in the active site of knowledge has been ap- of the recombinant pertussis vaccine the enzyme. These amino acid plied to design rationally changes render inactive the cat­ and to develop a geneti- 1984 The project starts alytic site and make the molecule cally engineered vaccine 1985 Cloning and sequencing of the pertussis toxin gene nontoxic' (Fig. 1). Therefore, the against pertussis that is 1987 Identification of the key amino acids to be changed by mutant molecule can be used in molecularly defined and mutagenesis to make a nontoxic derivative of pertussis toxin the vaccine without further chem­ 1988 Sequence of the gene coding for filamentous hemagglutinin that confers maximal pro- ical detoxification. This approach 1989 Construction of a Bordetello pertussis strain producing a tection from disease by nontoxic mutant of pertussis toxin offers several advantages. First, using low amounts of Phase I clinical trials the mutant PT exhibits none of antigens, thus providing a 1990 Phase II trials with acellular pertussis vaccine, alone (aP) or the toxic properties of the wild­ safe product. combined with diphtheria and tetanus (DTaP) type toxin, while retaining all This vaccine represents 1992 Beginning of the phase Ill efficacy trial with a DTaP vaccine other biological activities of the the first example of a mol- 1993 Approval and marketing of the aP vaccine in Italy molecule. Second, the genetically 19 ecule constructed by ra- 95 End of the phase Ill efficacy trial, approval and marketing of the engineered mutant PT is expected DTaP vaccine in Italy tional drug design that to retain the correct conformation 1996-97 Filing of the product license application worldwide has been proven effica­ of the wild-type toxin, and hence cious in a clinical trial, the conformational (neutralizing) showing that rational engineering may indeed be used to im­ epitopes known to exist in the five subunits of the toxin. In prove the effects and the safety of vaccines and possibly drugs. fact, a recent study using a panel of monoclonal antibodies (see Table 2) has shown that toxin-neutralizing epitopes were well The genetically engineered pertussis toxin: conserved in the genetically detoxified PT; however, these epi­ from the laboratory to a vaccine ... topes were destroyed by the chemical detoxification of PT, Pertussis toxin (PT) represents the key antigen in modern acel- which is usually used for vaccine production. Fig. 1 Schematic representation of the cavity containing the active site of pertussis toxin and rationale for genetic detoxification. The toxic activity of pertussis toxin is mediated by the ADP-ribosyl­ transferase ezymatic activity. During this reaction, the ADP-ribose group of NAD' is transferred to target proteins of eukaryotic cells. The active site of the enzyme is formed by a ~ strand and an a helix that make the floor and the ceiling of the cavity, and it contains two amino acids (Arg9 and Glul29) that are essential for catalysis. Following mutagenesis of the PT gene, to replace Arg9 with Lys and Glul29 with Gly, the mutant B. pertussis strain synthesizes a PT molecule that is enzymatically inactive and therefore nontoxic. The mutant PT molecule is the basis of the recombinant pertussis vaccine. 374 NATURE MEDICINE • VOLUME 3 • NUMBER 4 • APRIL 1997 © 1997 Nature Publishing Group http://www.nature.com/naturemedicine • COMMENTARY Table 2 Recognition of detoxified pertussis toxin fewer episodes of pertussis than did the recipients of by toxin-neutralizing monoclonal antibodies the vaccine containing chemically detoxified PT, in __________::.__ _____ -=.______________ -l the period from the first immunization to 1 month mAb PT specificity Wild-type PT* Genetically Chemically detoxified PT after the third immunization (Incomplete immu­ detoxified PT (formaldehyde) nization in Fig. 3), and in the period from 17 to 26 63.1 G9 51 1.00 0.86 <0.03 months after the third immunization (stage II in Fig. 63 .2 E3 51 1.00 1.07 <0.03 3). The protection induced by the two vaccines was 63.2 G12 51 1.00 0.78 <0.02 21.3 D12 B oligomer 1.00 1.10 <0.09 similar during the period from 1 to 17 months after 21.3 D9 52 + 53 1.00 1.36 <0.23 the third immunization (stage I in Fig. 3). 21 .3 Dll 52+ 53 1.00 1.51 <0.32 Immunogenicity studies showed that in spite of 47.4 53 + 54 1.00 3.84 <0.20 the lower antigen content, subjects who received ...:...;__:_20.6 _______53+ 54 _ ______________1.00 1.17 0_ ._18____ the vaccine containing the recombinant pertussis *Ra tio of soluble toxin to toxoid required for inhibition of binding of monoclonal antibodies toxin (composed of 5, 2.5 and 2.5 Jlg of PT, FHA and to solid-phase PT (ref. 10). PRN, respectively), had a higher antibody response ---'---------------=-=----::::::=======- against the PT component than those who received the vaccine containing chemically detoxified PT ... with improved immunogenicity ... (composed of 25, 25 and 8 Jlg of PT, FHA and PRN, respec­ In the final formulation, the vaccine contains the mutant PT tively), while, as expected from the higher antigen content, the (5 Jlg/dose), filamentous hemagglutinin (FHA; 2.5 Jlg/dose) and antibody response to FHA and PRN was higher for the latter Pertactin (PRN; 2.5 Jlg/dose). This vaccine has now been tested vaccine. in several phase II clinical trials. Valuable information was ob­ The vaccine containing the genetically detoxified PT, in spite tained from a trial performed by the National Institute of of having one-sixth as much protein, induced an earlier and Allergy and Infectious Diseases (NIAID) in the USA, where the longer lasting protection from disease. As the only difference safety and immunogenicity of this vaccine were compared with between the two vaccines resides in the antigenic quality of the those of eleven vaccines containing chemically detoxified PT. PT antigen, it is very likely that the observed superior protec­ Vaccines containing the recombinant PT induced an anti-PT tive efficacy of the vaccine containing the genetically detoxi­ response 10--20 times as high (on the basis of weight) as that fied PT is due to the PT antigen, which, in spite of being present from vaccines containing chemically inactivated PTs and had a in lower quantity, induces a better immune response. steeper dose-response curve (Fig. 2)"'. A qualitatively different immune response might explain why only during stage I, in coincidence with the very short ... and efficacy peak of the maximal antibody response (shown as a green The vaccine was tested in a double-blind, placebo-controlled curve in Fig. 3), the higher quantity of the chemically inacti­ efficacy trial performed in Italy, involving approximately vated PT (25 Jlg/dose) was able to induce a level of immunity 16,000 infants. The trial was sponsored by NIAID and per­ that could compensate for the antigenic quality of the geneti­ formed by the Istituto Superiore di Sanita in Rome. The results cally inactivated PT (5 Jlg/dose). In marked contrast, the low­ showed that the vaccine containing the genetically detoxified dose recombinant PT was able to protect better from disease PT was very efficacious (84o/o) in protecting from disease, and during the period of incomplete immunization and for an ex­ during the first 30 months of observation, the subjects had tended time after the third immunization (stage II), when the fewer pertussis cases (55 cases) than those administered an effi­ antibody titers are low and the quality of the memory response cacious acellular pertussis vaccine containing the same pertus­ is essential for protection. sis antigens, but prepared by conventional chemical The success of vaccination using recombinant PT is an example inactivation (81 cases) [ref. 6, 7 and Greco, D. et al., Int. of the importance of the quality of the immune response. Congress for Infectious Diseases, Abstr. (1996)]. Hence immunization may be improved by using high-quality A close look at the results of the trial revealed that recipients antigens that can be delivered in low doses and with fewer im­ of the vaccine containing genetically detoxified PT experienced munizations, which is preferable to the high doses and multi- 200.--------------------------, Detoxified PT: I=' 150 ::E A Genetically 8 • Chemically c~ 0 ~ 100 ~ >- '0 0 Fig.
Load more

Recommended publications
  • Pertussis Toxin
    Pertussis Toxin Publication Number MAN0004270 Revision Date 09 May 2011 Catalog Number: PHZ1174 Quantity: 50 μg Lot Number: See product label. Appearance: Lyophilized solid. Origin: Bordetella pertussis. Purity: >99%. This preparation migrates as five distinct bands when analyzed by SDS–Urea PAGE. The five bands correspond to one A protomer subunit, designated S1 (Mr=26.2 kDa), and four B oligomer subunits, designated S2- S5 (Mr’s= 21.9, 21.9, 12.1, and 10.9 kDa, respectively). Summary: Islet-activating protein Pertussis toxin consists of an A protomer subunit (S1) which possesses both NAD+ glycohydrolase and ADP–ribosyltransferase activities, and B oligomer subunits (S2, S3, S4, and S5) which are responsible for attachment of the native toxin to eukaryotic cell surfaces. Pertussis toxin uncouples G proteins from receptors by ADP ribosylating a cysteine residue near the carboxyl terminus of the α subunit. Biological Activity: The lowest concentration which produces a clustered growth pattern with CHO cells is 0.03 ng/mL. The adenylate cyclase activity of this preparation is 20.1 picomoles/minute/μg in the presence of 1 μg calmodulin. Reconstitution Reconstitute the contents of this vial with 500 μL sterile, distilled water. The composition of the solution will be Recommendation: 50 μg Pertussis toxin, 10 mM sodium phosphate, pH 7.0, 50 mM sodium chloride. Because Pertussis toxin is relatively insoluble, the resulting suspension should be made uniform by gentle mixing prior to withdrawing aliquots. It is important to note that this suspension should not be sterile-filtered. This preparation is not activated. For use with intact cells or extracts, activation is not necessary.
    [Show full text]
  • Biological Toxins Fact Sheet
    Work with FACT SHEET Biological Toxins The University of Utah Institutional Biosafety Committee (IBC) reviews registrations for work with, possession of, use of, and transfer of acute biological toxins (mammalian LD50 <100 µg/kg body weight) or toxins that fall under the Federal Select Agent Guidelines, as well as the organisms, both natural and recombinant, which produce these toxins Toxins Requiring IBC Registration Laboratory Practices Guidelines for working with biological toxins can be found The following toxins require registration with the IBC. The list in Appendix I of the Biosafety in Microbiological and is not comprehensive. Any toxin with an LD50 greater than 100 µg/kg body weight, or on the select agent list requires Biomedical Laboratories registration. Principal investigators should confirm whether or (http://www.cdc.gov/biosafety/publications/bmbl5/i not the toxins they propose to work with require IBC ndex.htm). These are summarized below. registration by contacting the OEHS Biosafety Officer at [email protected] or 801-581-6590. Routine operations with dilute toxin solutions are Abrin conducted using Biosafety Level 2 (BSL2) practices and Aflatoxin these must be detailed in the IBC protocol and will be Bacillus anthracis edema factor verified during the inspection by OEHS staff prior to IBC Bacillus anthracis lethal toxin Botulinum neurotoxins approval. BSL2 Inspection checklists can be found here Brevetoxin (http://oehs.utah.edu/research-safety/biosafety/ Cholera toxin biosafety-laboratory-audits). All personnel working with Clostridium difficile toxin biological toxins or accessing a toxin laboratory must be Clostridium perfringens toxins Conotoxins trained in the theory and practice of the toxins to be used, Dendrotoxin (DTX) with special emphasis on the nature of the hazards Diacetoxyscirpenol (DAS) associated with laboratory operations and should be Diphtheria toxin familiar with the signs and symptoms of toxin exposure.
    [Show full text]
  • Pertussis Toxin
    PLEASE POST THIS PAGE IN AREAS WHERE PERTUSSIS TOXIN IS USED IN RESEARCH LABORATORIES UNIVERSITY OF CALIFORNIA, SAN FRANCISCO ENVIRONMENT, HEALTH AND SAFETY/BIOSAFETY PERTUSSIS TOXIN EXPOSURE/INJURY RESPONSE PROTOCOL Organism or Agent: Pertussis Toxin Exposure Risk; Multiple Endocrine/Metabolic Effects Exposure Hotline Pager: 415/353-7842 (353-STIC) (Available 24 hours) Office of Environment, Health & Safety: 415/476-1300 (Available during work hours) 415/476-1414 or 9-911 (In case of emergency, available 24 hours) EH&S Biosafety Officer 415/514-2824 EH&S Public Health Officer: 415/514-3531 UCSF Occupational Health Services: 415/885-7580 (Available during work hours) California Poison Control: 800/222-1222 SFDPH Emergency Number: 415/554-2830 CDC Emergency Operations: 770/488-7100 _________________________________________________________________________ PROTOCOL SUMMARY In the event of an accidental exposure or injury, the protocol is as follows: 1. Modes of Exposure: a. Skin puncture or injection b. Ingestion c. Contact with mucous membranes (eyes, nose, mouth) d. Contact with non-intact skin e. Exposure to aerosols f. Respiratory exposure from inhalation of toxin 2. First Aid: a. Skin Exposure, immediately go to the sink and thoroughly wash the skin with soap and water. If working with pertussis, decontaminate any exposed skin with an antiseptic scrub solution. b. Skin Wound, immediately go to the sink and thoroughly wash the wound with soap and water and pat dry. c. Splash to Eye(s), Nose or Mouth, immediately flush the area with running water for at least 5- 10 minutes. d. Splash Affecting Garments, remove garments that may have become soiled or contaminated and place them in a double red plastic bag.
    [Show full text]
  • Human Peptides -Defensin-1 and -5 Inhibit Pertussis Toxin
    toxins Article Human Peptides α-Defensin-1 and -5 Inhibit Pertussis Toxin Carolin Kling 1, Arto T. Pulliainen 2, Holger Barth 1 and Katharina Ernst 1,* 1 Institute of Pharmacology and Toxicology, Ulm University Medical Center, 89081 Ulm, Germany; [email protected] (C.K.); [email protected] (H.B.) 2 Institute of Biomedicine, Research Unit for Infection and Immunity, University of Turku, FI-20520 Turku, Finland; arto.pulliainen@utu.fi * Correspondence: [email protected] Abstract: Bordetella pertussis causes the severe childhood disease whooping cough, by releasing several toxins, including pertussis toxin (PT) as a major virulence factor. PT is an AB5-type toxin, and consists of the enzymatic A-subunit PTS1 and five B-subunits, which facilitate binding to cells and transport of PTS1 into the cytosol. PTS1 ADP-ribosylates α-subunits of inhibitory G-proteins (Gαi) in the cytosol, which leads to disturbed cAMP signaling. Since PT is crucial for causing severe courses of disease, our aim is to identify new inhibitors against PT, to provide starting points for novel therapeutic approaches. Here, we investigated the effect of human antimicrobial peptides of the defensin family on PT. We demonstrated that PTS1 enzyme activity in vitro was inhibited by α-defensin-1 and -5, but not β-defensin-1. The amount of ADP-ribosylated Gαi was significantly reduced in PT-treated cells, in the presence of α-defensin-1 and -5. Moreover, both α-defensins decreased PT-mediated effects on cAMP signaling in the living cell-based interference in the Gαi- mediated signal transduction (iGIST) assay.
    [Show full text]
  • Release of Pertussis Toxin and Its Interaction with Outer-Membrane Antigens
    Journal of General Microbiology (1987), 133, 2427-2435. Printed in Great Britain 2427 Release of Pertussis Toxin and Its Interaction With Outer-membrane Antigens ByV. Y. PERERA, A. C. WARDLAW AND J. H. FREER* Department of Microbiology, University of Glasgow, Alexander Stone Building, Garscube Estate, Bearsden, Glasgow G61 IQH, UK (Received 16 December 1986 ;revised 22 April 1987) The absence of subunit S3 in cell-associated pertussis toxin (PT) from a mutant of Bordetella pertussis which failed to produce cell-free toxin suggested that this subunit was involved in the release of PT into the culture medium. The addition of methylated P-cyclodextrin (MCD) to the culture medium caused a small but consistent increase in the release of lipopolysaccharide (LPS) by four wild-type strains of B. pertussis. Since previous studies have shown that MCD also enhances the levels of PT in culture supernates, it seemed probable that the increased shedding of outer-membrane vesicles (OMV) may explain the increased levels of both cell-free PT and LPS. Release of PT was inhibited in media buffered with HEPES but was unaffected in Tris/HCl buffer. This suggested that in addition to shedding of the outer membrane, increased permeability and greater destabilization of the outer membrane, as caused by Tris/HCl buffer, may be important in the release of PT. Our data do not support the idea that PT is packaged into OMV because only an insignificant proportion (0.01 %) of the total cell-free PT was associated with LPS. The association of PT with small micelles derived from outer-membrane amphiphiles may be more important since the LPS content of PT purified from culture supernates (containing no large OMV) was nearly 18% by weight.
    [Show full text]
  • Safe Handling of Acutely Toxic Chemicals Safe Handling of Acutely
    Safe Handling of Acutely Toxic Chemicals , Mutagens, Teratogens and Reproductive Toxins October 12, 2011 BSBy Sco ttBthlltt Batcheller R&D Manager Milwaukee WI Hazards Classes for Chemicals Flammables • Risk of ignition in air when in contact with common energy sources Corrosives • Generally destructive to materials and tissues Energetic and Reactive Materials • Sudden release of destructive energy possible (e.g. fire, heat, pressure) Toxic Substances • Interaction with cells and organs may lead to tissue damage • EfftEffects are t tilltypically not general ltllti to all tissues, bttbut target tdted to specifi c ones • Examples: – Cancers – Organ diseases – Inflammation, skin rashes – Debilitation from long-term Poison Acute Cancer, health or accumulation with delayed (ingestion) risk reproductive risk emergence 2 Toxic Substances Are All Around Us Pollutants Natural toxins • Cigare tte smo ke • V(kidbt)Venoms (snakes, spiders, bees, etc.) • Automotive exhaust • Poison ivy Common Chemicals • Botulinum toxin • Pesticides • Ricin • Fluorescent lights (mercury) • Radon gas • Asbestos insulation • Arsenic and heavy metals • BPA ((pBisphenol A used in some in ground water plastics) 3 Application at UNL Chemicals in Chemistry Labs Toxin-producing Microorganisms • Chloro form • FiFungi • Formaldehyde • Staphylococcus species • Acetonitrile • Shiga-toxin from E. coli • Benzene Select Agent Toxins (see register) • Sodium azide • Botulinum neurotoxins • Osmium/arsenic/cadmium salts • T-2 toxin Chemicals in Biology Labs • Tetrodotoxin • Phenol
    [Show full text]
  • Cellular Activity of Salmonella Typhimurium Artab Toxin and Its Receptor-Binding Subunit
    toxins Article Cellular Activity of Salmonella Typhimurium ArtAB Toxin and Its Receptor-Binding Subunit Elise Overgaard 1, Brad Morris 2, Omid Mohammad Mousa 2 , Emily Price 3, Adriana Rodriguez 2, Leyla Cufurovic 2, Richard S. Beard 4 and Juliette K. Tinker 1,2,* 1 Biomolecular Sciences Graduate Program, Boise State University, Boise, ID 83725, USA; [email protected] 2 Department of Biology, Boise State University, Boise, ID 83725, USA; [email protected] (B.M.); [email protected] (O.M.M.); [email protected] (A.R.); [email protected] (L.C.) 3 Idaho Veterans Research and Education Foundation, Infectious Diseases Section, Boise, ID 83702, USA; [email protected] 4 Biomolecular Research Center, Boise State University, Boise, ID 83725, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-208-426-5472 Abstract: Salmonellosis is among the most reported foodborne illnesses in the United States. The Salmonella enterica Typhimurium DT104 phage type, which is associated with multidrug-resistant disease in humans and animals, possesses an ADP-ribosylating toxin called ArtAB. Full-length artAB has been found on a number of broad-host-range non-typhoidal Salmonella species and serovars. ArtAB is also homologous to many AB5 toxins from diverse Gram-negative pathogens, including cholera toxin (CT) and pertussis toxin (PT), and may be involved in Salmonella pathogenesis, however, in vitro cellular toxicity of ArtAB has not been characterized. artAB was cloned into E. coli and initially isolated using a histidine tag (ArtABHIS) and nickel chromatography. ArtABHIS was found to bind to African green monkey kidney epithelial (Vero) cells using confocal microscopy and to Citation: Overgaard, E.; Morris, B.; interact with glycans present on fetuin and monosialotetrahexosylganglioside (GM1) using ELISA.
    [Show full text]
  • Cloning and Sequencing of the Pertussis Toxin Genes
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 4631-4635, July 1986 Biochemistry Cloning and sequencing of the pertussis toxin genes: Operon structure and gene duplication (bacterial toxins/Bordetella peflussis/ADP-ribosylation/trnshlaonal signals/secreted proteins) ALFREDO NICOSIA*, MARIA PERUGINI*, CARLO FRANZINI*, MARIA CRISTINA CASAGLI*, MARIA GIUSEPPINA BORRI*, GUIDO ANTONI*, MARCO ALMONIt, PAOLO NERIt, GIULIO RATTI*, AND RINO RAPPUOLI*t *Sclavo Research Center, Via Fiorentina, 1, 53100 Siena, and tCRISMA, University of Siena "Le Scotte," 53100 Siena, Italy Communicated by A. M. Pappenheimer, Jr., February 26, 1986 ABSTRACT Pertussis toxin, a protein composed of five A B different subunits (S1, S2, S3, S4, and S5), is the major virulence factor of Bordetela pertussis. We have cloned and * sequenced a DNA fragment of 4.7 kilobases that contains the SiP.~ genes coding for the 'five subunits. The genes are clustered S3C. , within 3.2 kilobases in the following order: S1, S2, SA, S5, and S3. A sequence closely resembling Escherichia coli promoters is found only before the S1 gene, and a possible termination S5S 0 S1~~~~~~~~~~~~ S4 signal is present at the end of the S3 gene, which suggests that S4 -- - S5 the pertussis toxin genes are organized in a single operon. A possible Shine-Dalgarno sequence is present before the S1 gene but not before the other four genes that 8-12 nucleotides FIG. 1. NaDodSO4/polyacrylamide gel electrophoresis of affin- upstream from the ATG codon show a new consensus sequence, ity-purified PT. The toxin in lane A has been treated with a reducing 5'TCC(T)GG3', possibly involved in the regulation'of trans- agent before loading the gel.
    [Show full text]
  • Intracerebroventricular Antisense Knockdown of Gαi2 Results in Ciliary
    BMC Neuroscience BioMed Central Research article Open Access α Intracerebroventricular antisense knockdown of G i2 results in ciliary stasis and ventricular dilatation in the rat Kati S Mönkkönen*1, Juhana M Hakumäki2, Robert A Hirst3, Riitta A Miettinen4, Christopher O'Callaghan3, Pekka T Männistö5 and Jarmo T Laitinen6 Address: 1Department of Pharmacology & Toxicology, University of Kuopio, Kuopio, FIN-70211, Finland, 2Department of Biomedical NMR, National Bio-NMR Facility, A.I. Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, FIN-70211, Finland, 3Department of Infection, Immunity and Inflammation, University of Leicester, Leicester LE2 7LX, UK, 4Department of Neuroscience and Neurology, University of Kuopio, Finland and Department of Neurology, Kuopio University Hospital, Kuopio, FIN-70211, Finland, 5Division of Pharmacology & Toxicology, University of Helsinki, Helsinki, FIN-00014, Finland and 6Institute of Biomedicine, University of Kuopio, Kuopio, FIN-70211, Finland Email: Kati S Mönkkönen* - [email protected]; Juhana M Hakumäki - [email protected]; Robert A Hirst - [email protected]; Riitta A Miettinen - [email protected]; Christopher O'Callaghan - [email protected]; Pekka T Männistö - [email protected]; Jarmo T Laitinen - [email protected] * Corresponding author Published: 12 April 2007 Received: 7 September 2006 Accepted: 12 April 2007 BMC Neuroscience 2007, 8:26 doi:10.1186/1471-2202-8-26 This article is available from: http://www.biomedcentral.com/1471-2202/8/26 © 2007 Mönkkönen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • Differential Cholera-Toxin- and Pertussis-Toxin-Catalysed ADP-Ribosylation of G-Proteins Coupled to Formyl-Peptide and Leukotriene B4 Receptors Theresa M
    Biochem. J. Biochem. J. (1(1993)993) 289, 469-473 (Printed in Great Britain) 469 Differential cholera-toxin- and pertussis-toxin-catalysed ADP-ribosylation of G-proteins coupled to formyl-peptide and leukotriene B4 receptors Theresa M. SCHEPERS* and Kenneth R. McLEISHt Departments of Medicine and Biochemistry, University of Louisville Health Sciences Center and the Veterans Administration Medical Center, Louisville, KY 40292, U.S.A. N-Formylmethionyl-leucyl-phenylalanine (fMet-Leu-Phe) and imido]triphosphate and GDP in a concentration-dependent leukotriene B4 (LTB4) induce disparate second-messenger manner. Addition of fMet-Leu-Phe, but not LTB4, re-established generation and functional responses in neutrophils and HL-60 cholera-toxin labelling of a40 in the presence of either guanine granulocytes. Receptors for these chemoattractants couple to a nucleotide. In the absence of guanine nucleotides, fMet-Leu-Phe common pool of G-proteins which are substrates for both and C5a enhanced cholera-toxin-catalysed labelling of cc40, pertussis-toxin- and cholera-toxin-catalysed ADP-ribosylation. whereas LTB4 and platelet-activating factor had no effect. The hypothesis that formyl-peptide and LTB4 receptors induce Preincubation with fMet-Leu-Phe, but not LTB4, inhibited different receptor-specific conformations of activated G- pertussis-toxin labelling of a40 in the presence of guanosine 5'- proteins was tested. The ability of pertussis toxin and cholera [y-thio]triphosphate and in the absence of guanine nucleotides. toxin to ADP-ribosylate Gi proteins coupled to formyl-peptide Preincubation with fMet-Leu-Phe or LTB4 enhanced pertussis- or LTB4 receptors in membranes isolated from HL-60 toxin labelling of a40 in the presence of GDP.
    [Show full text]
  • Bordetella Virulence Factors
    Product Information Bordetella Virulence Factors Filamentous hemagglutinin (FHA) & Fimbriae 2/3 (Fim) The initial step in establishing a Bordetella pertussis infection is attachment of the bacteria to the epithelial lining of the host respiratory tract. Two B. pertussis virulence factors are key in this process, filamentous hemagglutinin (FHA)1 and fimbriae (Fim).2 FHA, which is both surface-associated and secreted by B. pertussis, is a multifunctional protein which promotes the attachment of the bacteria through several binding domains. Because FHA is highly immunogenic, it is included in many of the acellular vaccines. Additionally, FHA acts through multiple pathways to modulate the host immune response; an example of this type of activity is induction in macrophages of the secretion of both pro-inflammatory and anti-inflammatory cytokines.3,4 Fimbriae are extracellular proteins which, like FHA, participate in the attachment of bacteria to substrates. Based on their recognition by specific antisera, there are two fimbriae serotypes present in B. pertussis, fimbriae 2 (Fim 2) and fimbriae 3 (Fim 3).5 Both FHA, a large, 220 kDa -helical protein, and Fim 2/3 are produced by List Labs. FHA is from the native Bordetella pertussis strain 165 and the Fim 2/3 is isolated from cultures of a Pertactin (PRN) negative mutant derived from the Bordetella pertussis Wellcome strain 28 expressing a mixture of fimbriae 2 and fimbriae 3. Fimbriae are long structures which serve to tether the bacteria to surfaces. They are composed of subunits which dissociate in SDS producing components with apparent molecular weights of 22,500 and 22,000 Da for Fim 2 and Fim 3, respectively.5 Pertactin (PRN) and Lipopolysaccharide (LPS) Virulence factors located on the surface of Bordetella pertussis include pertactin and LPS.
    [Show full text]
  • The Immunological Basis for Immunization Series: Module 4: Pertussis (Immunological Basis for Immunization Series ; Module 4)
    WHO Immunological Basis for Immunization Series Module 4: Pertussis Update 2017 Department of Immunization, Vaccines and Biologicals World Health Organization 20, Avenue Appia CH-1211 Geneva 27, Switzerland [email protected] http://www.who.int/immunization/en/ Immunization, Vaccines and Biologicals The immunological basis for immunization series: module 4: pertussis (Immunological basis for immunization series ; module 4) ISBN 978-92-4-151317-3 © World Health Organization 2017 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The immunological basis for immunization series: module 4: pertussis.
    [Show full text]